Back to Investors
Investment Case
A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.
In 2022, the Group generated revenue of €2.1Bn, gross profit of €306.7m and EBITDA of €98.0m. With a workforce of more than 2,900, the Group is active in Ireland, Europe, USA, APAC and MENA.
Full Year 2022 Results
FY 2022 Key Stats
€98.0m
EBITDA
5.7%
Organic GP Growth YoY
17.3%
ROCE
18.4c
Adjusted EPS
Group Highlights
€306.7m
2022 GP
Employees
Partnering with 7 of the top 10 pharma companies
and 7 of the top 10 medical device companies
